Skip to main content
Figure 3 | Arthritis Research & Therapy

Figure 3

From: Discontinuation rates in clinical trials in musculoskeletal pain: meta-analysis from etoricoxib clinical trial reports

Figure 3

Clinical adverse event discontinuation: placebo, etoricoxib, and individual NSAIDs. Shown are the percentages of patients remaining after clinical adverse event (AE) discontinuation in studies conducted over 4 to 12 weeks with placebo, etoricoxib, and individual nonsteroidal anti-inflammatory drugs (NSAIDs). OA, osteoarthritis; RA, rheumatoid arthritis.

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us